what are the two glp 1 drugs GLP-1 all approved for glucose control in type 2 diabetes (T2D). Some of them also have additional indications reflecting their demonstrated benefits for cardiovascular disease, kidney health, and obesity. None GLP-1 Drugs and Type 1

The appearance of autoantibodies and clinical manifestations of autoimmune disease, including vitiligo, have been associated with statistically significant improvements in overall survival rates for patients with cutaneous melanoma

2.4 Interventional strategies for inflammation and oxidative stress 2.4.1 Anti-inflammatory drugs Inflammatory diseases such as ankylosing spondylitis and rheumatoid arthritis commonly cause bone loss through complex immune and inflammatory signaling pathways

Cagrilintide vs tirzepatide (Mounjaro/Zepbound) Mechanism: Cagrilintide: Amylin agonist Tirzepatide: Dual GIP/GLP-1 agonist Both novel approaches Weight loss: Cagrilintide: 10-12% monotherapy Tirzepatide: 15-22% monotherapy Tirzepatide superior as single agent Administration: Both: Weekly subcutaneous injection Both: Similar convenience Side effects: Cagrilintide: Strong GI effects Tirzepatide: Moderate GI effects Similar overall profile Approval status: Cagrilintide: Investigational Tirzepatide: FDA approved Tirzepatide available now Cost (when both available): Likely similar ($1,000-1,500/month) Both premium weight loss options Verdict: Currently, tirzepatide better choice (approved, superior weight loss)

doi: 10.1016/j.intimp.2025.114562 32 XueMYangFLeYYangYWangBJiaYet al

An SC measurement was performed on the laminae site of the dorsal horn